Odacova Health unveils long-term canine study at inaugural animal longevity summit

Odacova Health will reveal initial results from a nine-year dog study at Toronto’s Animal Longevity Summit, offering rare long-horizon data on pet healthspan. The company aims to disrupt the sector with a science-backed bionutrition approach that combines rigorous research with faster commercialisation prospects.

Odacova Health will emerge from stealth at the inaugural Animal Longevity Summit in Toronto, using the event to unveil an initial readout from a nine-year canine safety and efficacy study. The disclosure gives the young pet-health market a rare long-horizon dataset at a time when investors and researchers are seeking evidence that longevity claims can survive beyond short-term trials. The stakes are commercial as well as scientific: whichever companies can combine credible biology with a workable route to market may set the standards for companion-animal healthspan.

According to the company, the study spans molecular, transcriptomic, metabolic, functional and immune endpoints, making it unusually broad for a sector that often leans on smaller, shorter studies. Odacova says the work will not be fully disclosed; the complete dataset will be shared only with qualified partners under confidentiality.

The summit itself, billed by its organisers as the first global scientific conference devoted to animal healthspan, is scheduled for 1-2 October in Oakville, Ontario. Its programme will draw researchers, clinicians, founders and investors, with speakers including Matt Kaeberlein, Vera Gorbunova, Aubrey de Grey and Varun Dwaraka.

Odacova is positioning its approach as “bionutrition”: pharma-like rigour delivered through nutrition rather than a drug pipeline. The company says it is pursuing a GRAS-eligible route, signalling an ambition to commercialise faster than conventional therapeutics while still claiming a stronger evidence base than most pet food rivals.